Mapping proteins in chronic lymphocytic leukemia and Richter's Syndrome
Proteomics
Using advanced mass spectrometry to measure proteins and protein modifications in samples from people with CLL and Richter's Syndrome to find disease signals and potential treatment targets.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179182 on NIH RePORTER |
What this research studies
This project uses a proteomics core to deeply measure proteins and phosphoproteins in very small clinical samples using high-sensitivity mass spectrometry and multiplexed stable-isotope tagging (TMT 16-plex). The team combines protein-level data with genomic information to see which DNA changes actually change cell signaling. The focus is on understanding how chronic lymphocytic leukemia can transform into Richter's Syndrome. Dana‑Farber scientists will provide the proteomic data and analyses to support multiple related research projects.
Who could benefit from this research
Good fit: People with chronic lymphocytic leukemia, especially those with suspected or confirmed transformation to Richter's Syndrome or those willing to donate blood or tumor samples, would be the best fits.
Not a fit: People without CLL or those seeking immediate treatment changes are unlikely to get direct benefits from this laboratory-focused work.
Why it matters
Potential benefit: Could reveal new biomarkers and drug targets to help prevent or treat CLL that progresses to Richter's Syndrome.
How similar studies have performed: Proteogenomics and deep mass-spectrometry have identified important cancer pathways in other tumor types, but applying deep phosphoproteomics to CLL-to-Richter's transformation is relatively new.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Carr, Steven a — Dana-Farber Cancer Inst
- Study coordinator: Carr, Steven a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.